Gabriele Allegri

Gabriele Allegri is President of the Immuno Division at Diasorin as of May 2026. He brings over twenty years of international leadership experience across the Pharmaceuticals, Diagnostics, and MedTech sectors, developed at the intersection of science, innovation, market access, and commercial strategy, with a proven track record of leading global commercial organizations across the US, EMEA, and Asia.

Prior to joining Diasorin, he served as Vice President, Global Commercial Precision Medicine at Johnson & Johnson Innovative Medicine in North America, where he led global commercial strategies for precision medicine and companion diagnostics. He was Chair of the Precision Cancer Consortium (PCC) and a member of the Board of the Precision Medicine Coalition (PMC), actively contributing to the advancement of the global precision medicine agenda.

Throughout his career, he has played a key role in the development and scaling of global precision medicine strategies, with a strong focus on companion diagnostics, biomarker-driven therapies, and integrated go-to-market models. His experience spans the entire diagnostic-therapeutic continuum, from patient identification and testing strategies through to market access and stakeholder engagement, contributing to the adoption of precision medicine as a standard of care.

A distinctive element of his background is his strong commitment to diagnostic and clinical stewardship, promoting the responsible, data-driven use of diagnostics to improve patient outcomes and support the sustainability of healthcare systems.

Gabriele holds an MBA from Bocconi School of Management in Milan and a Master’s degree in Management Engineering from the University of Brescia, completed in collaboration with the University of Wuppertal in Germany and Université Paul Sabatier in France.